Claudio G. Brunstein
Expertise in
19
conditions

Dr. Claudio G. Brunstein

Hematology Oncology | Hematology | Oncology
10201 Carnegie Avenue, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
30 Years of Experience
Referral may be required
Before you request
Expertise in
19
conditions
10201 Carnegie Avenue, 
Cleveland, OH 

Overview

Claudio Brunstein is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 30 years.

Dr. Brunstein is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Brunstein is board certified in American Board Of Internal Medicine, 2017. He is actively involved in clinical research, co-authoring 169 peer reviewed articles and participating in 9 clinical trials. Dr. Brunstein is currently accepting new patients.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in MN

Board Certifications

American Board Of Internal Medicine, 2017

Fellowships

University of Minnesota

Hospital Affiliations

Cleveland Clinic
Mercy Medical Center
Akron General Medical Center

Languages Spoken

English
Portuguese

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 26 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
Other Locations
Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Enrollment Status: Recruiting
Publish Date: May 08, 2026
Intervention Type: Biological
Study Phase: Not Applicable
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: June 22, 2026
Intervention Type: Biological
Study Phase: Phase 3
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
Enrollment Status: Terminated
Publish Date: May 20, 2026
Intervention Type: Radiation, Drug, Biological
Study Drugs: Fludarabine, Cyclophosphamide, Cyclosporine A, Mycophenolate Mofetil, Umbilical Cord Blood
Study Phase: Not Applicable
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: February 25, 2026
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Radiation, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus, Anti-Thymocyte Globulin
Study Phase: Phase 2
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Study Phase: Phase 2
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

169 Total Publications

Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks.
Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks.
Journal: Transplantation and cellular therapy
Published: April 20, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Brian T. Hill
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Brian T. Hill
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Hill is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Hill is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hill is currently accepting new patients.

Expertise in
37
conditions
Dr. Paolo F. Caimi
Hematology Oncology | Hematology | Oncology
Expertise in
37
conditions
Dr. Paolo F. Caimi
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Paolo Caimi is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Caimi is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Caimi is board certified in American Board Of Internal Medicine, 2011. Dr. Caimi is currently accepting new patients.

Expertise in
24
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology
Expertise in
24
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Gerds is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gerds is board certified in American Board Of Internal Medicine, 2013. Dr. Gerds is currently accepting new patients.

Frequently Asked Questions about Dr. Claudio G. Brunstein

How do I make an appointment with Dr. Claudio G. Brunstein?

You can book an appointment with Dr. Claudio G. Brunstein by calling their office at 866-223-8100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Claudio G. Brunstein a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Claudio G. Brunstein is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Claudio G. Brunstein specialize in?

While Dr. Claudio G. Brunstein is a Hematology Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Claudio G. Brunstein participate in research or clinical trials?

Yes. Dr. Claudio G. Brunstein has published 169 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Claudio G. Brunstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Claudio G. Brunstein accept my insurance?

Dr. Claudio G. Brunstein accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 866-223-8100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brunstein's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile